crossover randomized trial
NCT01988545
GLP-1's Influence on Intestinal Blood Flow
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | native GLP-1 (7-36 amide) GLP-1 1.5 nmol/kg | lifestyle: none | 8 | 8 | |
| A2 | Glp1 9 36 amide GLP-1 9-36 amide 1.5 nmol/kg | lifestyle: none | 8 | 8 | |
| A3 | exenatide Exenatide 10 ug | lifestyle: none | 8 | 8 | |
| A4 | Placebo Saline | lifestyle: none | 8 | 8 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | GLP-1 1.5 nmol/kg A1 | Glp1 9 36 amide A2 | Exenatide 10 ug A3 | Placebo A4 | Whole trial ALL |
|---|---|---|---|---|---|---|
| age | mean (years) | 24.3 | ||||
| age | sd (years) | 2.7 | ||||
| bmi | mean (kg/m2) | 22.6 | ||||
| bmi | sd (kg/m2) | 2.1 | ||||
| female | n | 3 | ||||
| weight | mean (kg) | 71 | ||||
| weight | sd (kg) | 13 |